Effect of Chiglitazar and Sitagliptin on Bone Mineral Density and Body Composition in Untreated Patients with Type 2 Diabetes

References

• Napoli N, Chandran M, Pierroz DD, Abrahamsen B, Schwartz AV, Ferrari SL. Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol. 2017;13(4):208–219. doi:10.1038/nrendo.2016.153
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res. 2009;24(4):702–709. doi:10.1359/jbmr.081207
   PubMed Web of Science ®Google Scholar
• Anagnostis P, Gkekas NK, Achilla C, et al. Type 2 diabetes mellitus is associated with increased risk of sarcopenia: a systematic review and meta-analysis. Calcif Tissue Int. 2020;107(5):453–463. doi:10.1007/s00223-020-00742-y
   PubMed Web of Science ®Google Scholar
• Dede AD, Tournis S, Dontas I, Trovas G. Type 2 diabetes mellitus and fracture risk. Metabolism. 2014;63(12):1480–1490. doi:10.1016/j.metabol.2014.09.002
   PubMed Web of Science ®Google Scholar
• Koromani F, Ghatan S, van Hoek M, et al. Type 2 diabetes mellitus and vertebral fracture risk. Curr Osteoporos Rep. 2021;19(1):50–57. doi:10.1007/s11914-020-00646-8
   PubMed Web of Science ®Google Scholar
• Khosla S, Samakkarnthai P, Monroe DG, Farr JN. Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus. Nat Rev Endocrinol. 2021;17(11):685–697. doi:10.1038/s41574-021-00555-5
   PubMed Web of Science ®Google Scholar
• Brunzell JD. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia: response to Goldberg et al. Diabetes Care. 2005;28(12):2984–5; author reply 2985–6. doi:10.2337/diacare.28.12.2984
   Google Scholar
• Liu CH, Lee TH, Lin YS, Sung PS, Wei YC, Li YR. Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study. Cardiovasc Diabetol. 2020;19(1):2. doi:10.1186/s12933-019-0979-x
   PubMed Web of Science ®Google Scholar
• Wan Y. PPARγ in bone homeostasis. Trends Endocrinol Metab. 2010;21(12):722–728. doi:10.1016/j.tem.2010.08.006
   PubMedGoogle Scholar
• Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care. 2007;30(6):1574–1576. doi:10.2337/dc06-2606
   PubMed Web of Science ®Google Scholar
• Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2007;92(4):1305–1310. doi:10.1210/jc.2006-2646
   PubMed Web of Science ®Google Scholar
• Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2008;93(5):1696–1701. doi:10.1210/jc.2007-2249
   PubMed Web of Science ®Google Scholar
• Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000;405(6785):421–424. doi:10.1038/35013000
   PubMed Web of Science ®Google Scholar
• Mosti MP, Ericsson M, Erben RG, Schüler C, Syversen U, Stunes AK. The PPARα Agonist fenofibrate improves the musculoskeletal effects of exercise in ovariectomized rats. Endocrinology. 2016;157(10):3924–3934. doi:10.1210/en.2016-1114
   PubMed Web of Science ®Google Scholar
• Maltarollo VG, Kronenberger T, Windshugel B, Wrenger C, Trossini G, Honorio KM. Advances and challenges in drug design of PPARδ ligands. Curr Drug Targets. 2018;19(2):144–154. doi:10.2174/1389450118666170414113159
   PubMed Web of Science ®Google Scholar
• Scholtysek C, Katzenbeisser J, Fu H, et al. PPARβ/δ governs Wnt signaling and bone turnover. Nat Med. 2013;19(5):608–613. doi:10.1038/nm.3146
   PubMed Web of Science ®Google Scholar
• Mosti MP, Stunes AK, Ericsson M, et al. Effects of the peroxisome proliferator-activated receptor (PPAR)-δ agonist GW501516 on bone and muscle in ovariectomized rats. Endocrinology. 2014;155(6):2178–2189. doi:10.1210/en.2013-1166
   PubMed Web of Science ®Google Scholar
• Reichkendler MH, Auerbach P, Rosenkilde M, et al. Exercise training favors increased insulin-stimulated glucose uptake in skeletal muscle in contrast to adipose tissue: a randomized study using FDG PET imaging. Am J Physiol Endocrinol Metab. 2013;305(4):E496–506. doi:10.1152/ajpendo.00128.2013
   PubMed Web of Science ®Google Scholar
• Cowan TE, Brennan AM, Stotz PJ, Clarke J, Lamarche B, Ross R. Separate effects of exercise amount and intensity on adipose tissue and skeletal muscle mass in adults with abdominal obesity. Obesity. 2018;26(11):1696–1703. doi:10.1002/oby.22304
   PubMed Web of Science ®Google Scholar
• Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care. 2000;23(8):1067–1071. doi:10.2337/diacare.23.8.1067
   PubMed Web of Science ®Google Scholar
• Tankó LB, Bagger YZ, Alexandersen P, Larsen PJ, Christiansen C. Peripheral adiposity exhibits an independent dominant antiatherogenic effect in elderly women. Circulation. 2003;107(12):1626–1631. doi:10.1161/01.CIR.0000057974.74060.68
   PubMed Web of Science ®Google Scholar
• He BK, Ning ZQ, Li ZB, et al. In vitro and in vivo characterizations of Chiglitazar, a newly identified PPAR pan-agonist. PPAR Res. 2012;2012:546548. doi:10.1155/2012/546548
   PubMed Web of Science ®Google Scholar
• Pan DS, Wang W, Liu NS, et al. Chiglitazar preferentially regulates gene expression via configuration-restricted binding and phosphorylation inhibition of PPARγ. PPAR Res. 2017;2017:4313561. doi:10.1155/2017/4313561
   PubMed Web of Science ®Google Scholar
• Gross B, Pawlak M, Lefebvre P, Staels B. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat Rev Endocrinol. 2017;13(1):36–49. doi:10.1038/nrendo.2016.135
   PubMed Web of Science ®Google Scholar
• Li X, Yu J, Wu M, et al. Pharmacokinetics and Safety of Chiglitazar, a peroxisome proliferator-activated receptor pan-agonist, in patients < 65 and ≥ 65 years with type 2 diabetes. Clin Pharmacol Drug Dev. 2021;10(7):789–796. doi:10.1002/cpdd.893
   PubMed Web of Science ®Google Scholar
• Xu HR, Zhang JW, Chen WL, Ning ZQ, Li XN. Pharmacokinetics, safety and tolerability of chiglitazar, A Novel Peroxisome Proliferator-Activated Receptor (PPAR) pan-agonist, in healthy Chinese volunteers: a phase i study. Clin Drug Investig. 2019;39(6):553–563. doi:10.1007/s40261-019-00779-4
   PubMed Web of Science ®Google Scholar
• Wang Y, Li H, Gao H, et al. Effect of chiglitazar and sitagliptin on glucose variations, insulin resistance and inflammatory-related biomarkers in untreated patients with type 2 diabetes. Diabet Res Clin Pract. 2022;183:109171. doi:10.1016/j.diabres.2021.109171
   PubMed Web of Science ®Google Scholar
• Kato H, Nagai Y, Ohta A, et al. Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes. Diabet Res Clin Pract. 2015;109(1):199–205. doi:10.1016/j.diabres.2015.04.008
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int. 2009;84(1):45–55. doi:10.1007/s00223-008-9195-5
   PubMed Web of Science ®Google Scholar
• Lee HS, Yoon JS, Park KJ, Lim JS, Hwang JS. The relationship between bone mineral density and type 2 diabetes in obese children and adolescents at the time of initial diagnosis. Horm Metab Res. 2019;51(1):42–46. doi:10.1055/a-0755-2799
   PubMed Web of Science ®Google Scholar
• Abdulameer SA, Sulaiman SA, Hassali MA, Subramaniam K, Sahib MN. Osteoporosis and type 2 diabetes mellitus: what do we know, and what we can do. Patient Prefer Adherence. 2012;6:435–448. doi:10.2147/PPA.S32745
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001;86(1):32–38. doi:10.1210/jcem.86.1.7139
   PubMed Web of Science ®Google Scholar
• Strotmeyer ES, Cauley JA, Schwartz AV, et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med. 2005;165(14):1612–1617. doi:10.1001/archinte.165.14.1612
   PubMedGoogle Scholar
• Gilbert MP, Pratley RE. The impact of diabetes and diabetes medications on bone health. Endocr Rev. 2015;36(2):194–213. doi:10.1210/er.2012-1042
   PubMed Web of Science ®Google Scholar
• Kanazawa I, Yamaguchi T, Yano S, et al. Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. Osteoporos Int. 2010;21(12):2013–2018. doi:10.1007/s00198-009-1161-1
   PubMed Web of Science ®Google Scholar
• Lecka-Czernik B. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep. 2010;8(4):178–184. doi:10.1007/s11914-010-0027-y
   PubMedGoogle Scholar
• Lecka-Czernik B. PPARs in bone: the role in bone cell differentiation and regulation of energy metabolism. Curr Osteoporos Rep. 2010;8(2):84–90. doi:10.1007/s11914-010-0016-1
   PubMedGoogle Scholar
• Qian G, Fan W, Ahlemeyer B, Karnati S, Baumgart-Vogt E. Peroxisomes in different skeletal cell types during intramembranous and endochondral ossification and their regulation during osteoblast differentiation by distinct peroxisome proliferator-activated receptors. PLoS One. 2015;10(12):e0143439. doi:10.1371/journal.pone.0143439
   PubMed Web of Science ®Google Scholar
• Still K, Grabowski P, Mackie I, Perry M, Bishop N. The peroxisome proliferator activator receptor alpha/delta agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo. Calcif Tissue Int. 2008;83(4):285–292. doi:10.1007/s00223-008-9175-9
   PubMed Web of Science ®Google Scholar
• Kaul S, Rothney MP, Peters DM, et al. Dual-energy X-ray absorptiometry for quantification of visceral fat. Obesity. 2012;20(6):1313–1318. doi:10.1038/oby.2011.393
   PubMed Web of Science ®Google Scholar
• Micklesfield LK, Goedecke JH, Punyanitya M, Wilson KE, Kelly TL. Dual-energy X-ray performs as well as clinical computed tomography for the measurement of visceral fat. Obesity. 2012;20(5):1109–1114. doi:10.1038/oby.2011.367
   PubMed Web of Science ®Google Scholar
• De Pergola G, Tartagni M, d’Angelo F, et al. Abdominal fat accumulation, and not insulin resistance, is associated to oligomenorrhea in non-hyperandrogenic overweight/obese women. J Endocrinol Invest. 2009;32(2):98–101. doi:10.1007/BF03345694
   PubMed Web of Science ®Google Scholar
• Weiping J, Jianhua M, Heng M, et al. Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, Phase 3 trial (CMAS). Sci Bull (Beijing). 2021;66(15):1581–1590.
   PubMed Web of Science ®Google Scholar
• Aucouturier J, Meyer M, Thivel D, Taillardat M, Duché P. Effect of android to gynoid fat ratio on insulin resistance in obese youth. Arch Pediatr Adolesc Med. 2009;163(9):826–831. doi:10.1001/archpediatrics.2009.148
   PubMedGoogle Scholar
• Lim S, Kim JH, Yoon JW, et al. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA). Diabetes Care. 2010;33(7):1652–1654. doi:10.2337/dc10-0107
   PubMed Web of Science ®Google Scholar
• Fu X, Ma X, Lu H, He W, Wang Z, Zhu S. Associations of fat mass and fat distribution with bone mineral density in pre- and postmenopausal Chinese women. Osteoporos Int. 2011;22(1):113–119. doi:10.1007/s00198-010-1210-9
   PubMed Web of Science ®Google Scholar
• Wiklund P, Toss F, Weinehall L, et al. Abdominal and gynoid fat mass are associated with cardiovascular risk factors in men and women. J Clin Endocrinol Metab. 2008;93(11):4360–4366. doi:10.1210/jc.2008-0804
   PubMed Web of Science ®Google Scholar
• Hou XG, Moser S, Sarr MG, Thompson GB, Que FG, Jensen MD. Visceral and subcutaneous adipose tissue diacylglycerol acyltransferase activity in humans. Obesity. 2009;17(6):1129–1134. doi:10.1038/oby.2008.659
   PubMed Web of Science ®Google Scholar
• Toss F, Wiklund P, Franks PW, et al. Abdominal and gynoid adiposity and the risk of stroke. Int J Obes Lond. 2011;35(11):1427–1432. doi:10.1038/ijo.2011.9
   PubMed Web of Science ®Google Scholar
• Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20(6):1595–1599. doi:10.1161/01.ATV.20.6.1595
   PubMed Web of Science ®Google Scholar
• Kim JY, van de Wall E, Laplante M, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest. 2007;117(9):2621–2637. doi:10.1172/JCI31021
   PubMed Web of Science ®Google Scholar
• Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab. 2014;20(4):573–591. doi:10.1016/j.cmet.2014.08.005
   PubMed Web of Science ®Google Scholar
• Watanabe S, Takeuchi Y, Fukumoto S, Fujita H, Nakano T, Fujita T. Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J Bone Miner Metab. 2003;21(3):166–171. doi:10.1007/s007740300026
   PubMed Web of Science ®Google Scholar